Please login to the form below

Not currently logged in
Email:
Password:

PD-1

This page shows the latest PD-1 news and features for those working in and with pharma, biotech and healthcare.

FDA approval for Merck’s Keytruda threatens Libtayo in skin cancer

FDA approval for Merck’s Keytruda threatens Libtayo in skin cancer

Approval of Merck’s market-leading PD-1 inhibitor in this indication is a shot across the bows of Sanofi and Regeneron, which picked up FDA approval for Libtayo in cSCC – ... Libtayo was the sixth drug in the PD-1/PD-L1 inhibitor class to reach the

Latest news

More from news
Approximately 28 fully matching, plus 345 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    The confounding issue is that, in the case of PD-1/PD-L1 drugs, each developer uses its own companion diagnostic that is required to prescribe the drug. ... Harmonisation has been addressed in this case by the development of a ‘complementary’

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the ... hope was that - without the brake of PD-1 – the edited cells

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    However this class of drugs aren’t miracle cures: many patients and tumour types do not respond to PD-1/PD-L1s – the overall response rate (ORR) is commonly well below ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... 1 inhibitor Keytruda (pembrolizumab) was backed for cancers

  • Is China ready for a pharmaceutical gold rush?

    The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.

More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics